Literature DB >> 17270609

Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome.

Seok-Soo Byun1, Woon Geol Yeo, Sang Eun Lee, Eunsik Lee.   

Abstract

OBJECTIVES: To investigate the expression of survivin in renal cell carcinoma and try to define its association with certain pathologic features and the clinical outcome.
METHODS: The tissue samples from 85 consecutive renal cell carcinoma specimens were obtained from patients who had undergone radical or partial nephrectomy. The mean follow-up was 45 months (range 3 to 60). Immunohistochemical staining of the paraffin sections of the pathologic sample was performed using monoclonal antibody for survivin with the standard avidin-biotin-peroxidase technique. The mean expression rate of survivin was assessed by inspection of at least five microscopic fields at 400x magnification. Expression of survivin was considered positive when more than 10% of the cancer cells in the microscopic fields demonstrated immunostaining. The degree of expression of survivin was compared with the clinicopathologic features.
RESULTS: Survivin was expressed in 67 (79%) of 85 samples. Immunostaining for survivin was demonstrated in the cytoplasm of tumor cells and in vascular endothelial cells. A significant increase in survivin expression was associated with increased T stage (P = 0.044), increased tumor grade (P = 0.0013), and low recurrence-free survival (P = 0.046). Multivariate Cox regression analysis revealed that survivin expression is an independent prognostic parameter (P = 0.021) in renal cell carcinoma.
CONCLUSIONS: The results of this study suggest that survivin-mediated inhibition of apoptosis is associated with progression and recurrence of renal cell carcinoma. Thus, survivin is a useful independent prognostic marker for this condition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17270609     DOI: 10.1016/j.urology.2006.09.024

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  22 in total

1.  Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.

Authors:  Francesca De Iuliis; Gerardo Salerno; Anna Giuffrida; Bernardina Milana; Ludovica Taglieri; Giovanna Rubinacci; Sabrina Giantulli; Federica Terella; Ida Silvestri; Susanna Scarpa
Journal:  Tumour Biol       Date:  2015-09-21

2.  Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance.

Authors:  Yu Lei; Zhang Geng; Wu Guo-Jun; Wang He; Yuan Jian-Lin
Journal:  Mol Cell Biochem       Date:  2010-06-19       Impact factor: 3.396

3.  Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.

Authors:  Fiona M Foster; Thomas W Owens; Jolanta Tanianis-Hughes; Robert B Clarke; Keith Brennan; Nigel J Bundred; Charles H Streuli
Journal:  Breast Cancer Res       Date:  2009-06-29       Impact factor: 6.466

Review 4.  Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers.

Authors:  Paul L Crispen; Stephen A Boorjian; Christine M Lohse; Bradley C Leibovich; Eugene D Kwon
Journal:  Cancer       Date:  2008-08-01       Impact factor: 6.860

5.  Upregulation of centromere protein H is associated with progression of renal cell carcinoma.

Authors:  Xun Wu; Youcheng Lin; Liping Shi; Yi Huang; Caiyong Lai; Yongqiang Wang; Meng Zhang; Shupeng Wang; Baoli Heng; Ganshen Yu; Xinghua Du; Lu Fang; Yu Fu; Jie Chen; Zexiong Guo; Zexuan Su; Song Wu
Journal:  J Mol Histol       Date:  2015-08-07       Impact factor: 2.611

6.  External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma.

Authors:  Nathan E Hoffmann; Yuri Sheinin; Christine M Lohse; Alexander S Parker; Bradley C Leibovich; Zhong Jiang; Eugene D Kwon
Journal:  Cancer       Date:  2008-04-01       Impact factor: 6.860

Review 7.  Nanopreparations to overcome multidrug resistance in cancer.

Authors:  Niravkumar R Patel; Bhushan S Pattni; Abraham H Abouzeid; Vladimir P Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2013-08-23       Impact factor: 15.470

8.  Molecular profiling of small renal masses: Current status and future directions.

Authors:  Balaji Kalyanaraman; Krishnanath Gaitonde; James F Donovan
Journal:  Indian J Urol       Date:  2009 Oct-Dec

9.  Seeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma - apoptosis-regulating factors.

Authors:  Beata Młot; Cezary Szczylik; Piotr Rzepecki
Journal:  Contemp Oncol (Pozn)       Date:  2012-02-29

10.  Prognostic biomarkers of renal cell carcinoma: Recent advances.

Authors:  Hiroshi Kitamura; Taiji Tsukamoto
Journal:  Indian J Urol       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.